Gilead hepatitis C drug shows promise in late-stage trial
(Reuters) - Gilead Sciences said a late-stage trial of its experimental hepatitis C treatment showed that the virus was not detected in 78 percent of patients taking the drug, 12 weeks after completing therapy.
The trial, named Positron, was testing the drug, sofosbuvir, in patients who were unable or unwilling to take interferon -- a standard hepatitis C drug known for its unpleasant side effects.
No patient in the placebo group achieved an undetectable virus level 12 weeks after completing the therapy, Gilead said.
The safety profile of the drug was similar to that observed in prior studies, and there were few treatment discontinuations due to adverse events, Gilead said.
The company said it would submit the full data from the study for presentation at a scientific conference and will share data from additional late-stage studies in early 2013.
Gilead expects to submit its first regulatory filings for sofosbuvir by mid-2013, Chief Scientific Officer Norbert Bischofberger said.
(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)
- Tweet this
- Share this
- Digg this
- China's Xiaomi hopes Mi 4 smartphone can take on Apple
- Rebels likely downed Malaysian jet 'by mistake' - U.S. officials
- Nifty hits record high on foreign buying, higher Asian stocks
- Jet Airways chairman says looking to restructure debts, talking to bankers
- Italy gives Google 18 months to change data use practices
Saudi scientists have found gene fragments of the deadly Middle East Respiratory Syndrome (MERS) virus in air from a barn housing an infected camel and say this suggests the disease may be transmitted through the air. Full Article
'Bad' laws hurt sex workers, gays from Uganda to Nepal, AIDS meeting told. Full Article
Sierra Leone religious leaders criticise government handling of Ebola. Full Article